OVID THERAPEUTICS INC. (NASDAQ: OVID) Files An 8-K Other Events

0
OVID THERAPEUTICS INC. (NASDAQ: OVID) Files An 8-K Other Events

OVID THERAPEUTICS INC. (NASDAQ: OVID) Files An 8-K Other Events
Item 8.01.Other Events.

On December 6, 2018, Ovid Therapeutics Inc. (the “Company”) issues a Press Release announcing plans to move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome.

A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form8-Kand is incorporated herein by reference.

Item 8.01.Financial Statements and Exhibits

(d) Exhibit

Exhibit No.

Description

99.1

Press Release, dated December 6, 2018


Ovid Therapeutics Inc. Exhibit
EX-99.1 2 ovid-ex991_6.htm EX-99.1 ovid-ex991_6.htm Exhibit 99.1   Ovid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome   — Single pivotal Phase 3 trial design,…
To view the full exhibit click here